Gilead Sciences Announces New Cancer Therapy Data Presentations

Gilead Sciences (NASDAQ:GILD) will present over 25 abstracts at the ASCO Annual Meeting and EHA Congress, showcasing progress in cancer therapies including new Phase 3 data for Trodelvy and anito-cel. The company also reported positive interim results from its drug Livdelzi for primary biliary cholangitis.

By Venkatesh Mon, June 1, 2026 at 4:43 PM GMT+3 2 min read · Yahoo Finance · June 1, 2026, 13:43 UTC

Gilead Sciences Announces New Cancer Therapy Data Presentations

Tickers: $GILD

Topics: anito-cel ASCO meeting cancer therapy CAR T-cell therapies EHA Congress KITE-753 Trodelvy

Read the full article at Yahoo Finance

More World news

Spout Finance Integrates Ondo Stocks to Enable Interest-Free USDC Borrowing via Covered Calls PR Newswire · November 12, 2026, 14:30 UTC
Deswell Industries Announces Semi-Annual Dividend of $0.10 Per Share Seeking Alpha · November 12, 2026, 14:24 UTC
Nvidia Shares Plunge Following Announcement of CEO Jensen Huang's Resignation Seeking Alpha · November 12, 2026, 14:24 UTC
Archer Aviation Enters Multi-Year Partnership with Formula One Seeking Alpha · November 12, 2026, 14:16 UTC
Edgewell Personal Care Announces Quarterly Dividend of $0.15 Per Share Seeking Alpha · November 12, 2026, 14:16 UTC
Hudbay Minerals Announces Quarterly Dividend of CAD 0.01 Per Share Seeking Alpha · November 12, 2026, 14:16 UTC
Warby Parker Unveils AI-Powered Intelligent Eyewear Collection in Partnership with Google and Samsung Seeking Alpha · November 12, 2026, 14:17 UTC
Where Food Comes From Reports Q3 Revenue Growth and Improved Gross Margins Seeking Alpha · November 12, 2026, 14:17 UTC
Medical Care Technologies Inc. Reports Q3 Revenue Growth and Significant Net Income Increase Seeking Alpha · November 12, 2026, 14:17 UTC
Digi International Reports Record Fiscal 2026 Results and Announces Acquisition of Disruptive Technologies Motley Fool · November 12, 2026, 14:15 UTC